We conclude that patients with mCRC have higher VEGF-A, -B, -C, -D, PlGF, VEGFR-1, -2, and -3 proteins in tumor tissues than non-mCRC patients, and higher circulating levels of VEGF-A, -B, -C, -D, and PlGF proteins. This evidence concerns the gene PGF and neoplasm.